CN111187827A - Parkinson disease biomarker and application thereof - Google Patents
Parkinson disease biomarker and application thereof Download PDFInfo
- Publication number
- CN111187827A CN111187827A CN202010065567.2A CN202010065567A CN111187827A CN 111187827 A CN111187827 A CN 111187827A CN 202010065567 A CN202010065567 A CN 202010065567A CN 111187827 A CN111187827 A CN 111187827A
- Authority
- CN
- China
- Prior art keywords
- disease
- parkinson
- circ
- rna
- biomarker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to a Parkinson disease biomarker and application thereof. The invention provides a biomarker for Parkinson's disease, wherein the biomarker is circular RNA, the circular RNA is circ-AMOTL1, and the circ-AMOTL1 is a nucleotide sequence containing SEQ ID NO. 1. The invention provides a method for diagnosing and predicting the risk of the Parkinson's disease or related diseases at an early stage, which can overcome the defects that the existing Parkinson's disease diagnosis method cannot realize early warning, cannot predict the Parkinson's disease and the like.
Description
Technical Field
The invention relates to the technical field of biomedicine, and particularly relates to a Parkinson disease biomarker and application thereof.
Background
Parkinson's Disease (PD) is a common degenerative disease of the central nervous system, and the pathogenesis of the PD is that dopaminergic neurons of the nigrostriatal body are gradually lost, so that symptoms such as resting tremor, bradykinesia, muscular rigidity, gait disorder and the like are caused, the health and the life quality of a patient are seriously influenced, and the burden of deposition is brought to the patient and families and society of the patient. At present, PD clinical diagnosis mainly depends on comprehensive evaluation of medical history, symptoms, physical signs and imaging, but the methods have the defects of high subjectivity, low reliability, high cost and the like. In addition, early intervention can significantly improve the quality of life and prolong life time of PD patients, while dopaminergic neurons are mostly lost when patients already present with symptoms, signs, missing early intervention opportunities.
Therefore, there is still a need for improvement in the early diagnosis and discovery of parkinson's disease.
Disclosure of Invention
The present invention is directed to solving, at least to some extent, one of the technical problems in the related art. To this end, it is an object of the present invention to provide a biomarker for parkinson's disease. The expression change of the biomarker is earlier than the neuron loss, and the biomarker can be used for early prediction of Parkinson's disease.
To this end, in a first aspect of the invention, the invention proposes a biomarker for parkinson's disease, the biomarker being a circular RNA, the circular RNA being circ-AMOTL1, the circ-AMOTL1 being a nucleotide sequence comprising SEQ id no: 1.
According to the biomarker for the Parkinson disease, the expression of the biomarker is increased in the blood of a Parkinson disease patient and also increased in the blood and midbrain tissue of an MPTP-induced Parkinson disease animal model by detecting the circular RNA circ-AMOTL1, and the expression change of the biomarker is earlier than the loss of neurons, so that the biomarker can be used for early prediction of the Parkinson disease. Has the advantages of objectivity, sensitivity, simplicity, low cost and the like, and can indicate the risk of the Parkinson's disease at an early stage.
In a second aspect of the invention, the invention proposes a method of diagnosing whether a subject has, or is predictive of the risk of, parkinson's disease or a related disease, for non-disease diagnostic purposes, comprising:
(1) collecting a peripheral blood sample from the subject;
(2) extracting RNA of the peripheral blood sample, performing reverse transcription amplification on the RNA, and then performing fluorescent quantitative PCR (polymerase chain reaction) to detect the expression amount of the circ-AMOTL 1.
According to the method of the present invention, the amount of expression of the biomarker in the subject is detected to determine whether the subject has, or is predicted to be at risk for having, parkinson's disease or a related disease.
In a third aspect of the invention, the invention provides a kit comprising reagents for detecting the biomarkers described above.
In a fourth aspect of the invention, the invention proposes the use of a biomarker as defined above in the manufacture of a kit for diagnosing whether a subject has, or predicting the risk of, parkinson's disease or a related disease.
According to an embodiment of the invention, the diagnosing or predicting comprises the steps of:
(1) collecting a peripheral blood sample from the subject;
(2) extracting RNA of the peripheral blood sample, performing reverse transcription amplification on the RNA, and then performing fluorescent quantitative PCR (polymerase chain reaction) to detect the expression amount of the circ-AMOTL 1.
Detecting the expression level of the biomarker in the subject is used to determine whether the subject has, or is predicted to be at risk for having, parkinson's disease or a related disease.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Drawings
FIG. 1 is a graph of the expression of circ-AMOTL1 in the blood of PD patients;
FIG. 2 shows the expression of circ-AMOTL1 in blood of PD mice;
FIG. 3 is the expression of circ-AMOTL1 in brain tissue in PD mice;
FIG. 4 is the number of brain TH positive neurons in a PD mouse of circ-AMOTL1 of the invention.
Detailed Description
The technical solution of the present invention is illustrated by specific examples below. It is to be understood that one or more method steps mentioned in the present invention do not exclude the presence of other method steps before or after the combination step or that other method steps may be inserted between the explicitly mentioned steps; it should also be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Moreover, unless otherwise indicated, the numbering of the various method steps is merely a convenient tool for identifying the various method steps, and is not intended to limit the order in which the method steps are arranged or the scope of the invention in which the invention may be practiced, and changes or modifications in the relative relationship may be made without substantially changing the technical content.
In order to better understand the above technical solutions, exemplary embodiments of the present invention are described in more detail below. While exemplary embodiments of the invention have been shown, it should be understood that the invention may be embodied in various forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
Aiming at the defects that the existing Parkinson disease diagnosis method can not realize early warning and can not predict the onset and development trend of the Parkinson disease, the invention provides a biomarker for assessing the risk of the Parkinson disease or early diagnosing the Parkinson disease, a diagnosis and disease risk assessment method of the Parkinson disease, a method for predicting the onset and development trend of the Parkinson disease and an application of the method to disease pathological typing.
Biomarkers
According to one aspect of the invention, the invention provides a biomarker which is a circular RNA, the circular RNA is circ-AMOTL1, and the circ-AMOTL1 is a nucleotide sequence comprising:
according to an embodiment of the invention, the level of the biomarker substance is indicated by its expression level. The detection of the expression level of the circular RNA circ-AMOTL1 can comprise detection methods such as RT-PCR, fluorescent quantitative PCR, in-situ hybridization or chip and the like.
The invention will now be described with reference to specific examples, which are intended to be illustrative only and not to be limiting in any way.
Example 1 human peripheral blood circ-AMOTL1 expression assay
1. Human blood sample collection
10 peripheral blood samples were collected from PD (Parkinson's disease) patients, and 10 peripheral blood samples from normal persons.
Blood sample RNA extraction, reverse transcription and fluorescent quantitative PCR
(1) RNA extraction: according to the procedure of the instruction, RNA of the blood sample was extracted using a blood RNA extraction kit of TAKARA. Mu.l of the finally obtained RNA was taken out and quantified.
(2) Reverse transcription: the following was performed using a reverse transcription kit from MedChemExpress, according to the instructions:
reaction system:
2×Super RT Mix 10μL
Total RNA 1μg
RNase-Free H2O To 20μL
reaction conditions are as follows:
the first step is as follows: 10 minutes at 25 ℃;
the second step is that: 45 minutes at 42 ℃;
the third step: at 85 ℃ for 2 minutes.
(3) Fluorescent quantitative PCR: according to the instruction steps, the fluorescent quantitative PCR kit of SYBR Green method of Promega company is used for carrying out:
reaction system:
Human circ-AMOTL1 Forward Primer：AGTATGGGGTAACGAGTTGAAGAT(SEQ ID NO:2)。
Human circ-AMOTL1 Reverse Primer：AGTTGTTCCTGGATCAGCCG(SEQ ID NO:3)。
reaction conditions are as follows:
the first step is as follows: 2 minutes at 95 ℃;
the second step is that: at 95 ℃ for 15 seconds, at 60 ℃ for 1 minute, for 40 cycles;
the third step: analyzing and determining a target band by a melting curve at 60-95 ℃;
the fourth step: the Δ Δ CT method was used for relative quantification.
3. Results
As shown in FIG. 1, the expression of circ-AMOTL1 was elevated in the blood of PD patients compared to normal human blood, and the difference was statistically significant (p < 0.05).
Example 2 detection of mouse peripheral blood Circ-AMOTL1 expression and dopaminergic neuron enumeration
1. Model building
The scheme utilizes an international commonly used PD mouse model: 32 male C57BL mice, 10 weeks old, were randomly divided into four groups, PD 1 day group, PD 7 day group, control 1 day group, control 7 day group. Mice in PD 1 day group and PD 7 day group were intraperitoneally injected with 1-methyl-4-phenyl-1, 2,4, 5-tetrahydropyridine (MPTP) at a dose of 30mg/kg for 5 days, and control 1 day group and control 7 day group were injected with an equal dose of physiological saline.
2. Mouse sample collection
On day 1 after the last injection, blood and a brain tissue sample are taken after mice in the PD 1 day group and the control 1 day group are anesthetized, or a whole brain tissue sample is taken after sequentially perfusing and fixing the mice by physiological saline and 4% paraformaldehyde through an aorta.
3. RNA extraction, reverse transcription and fluorescent quantitative PCR of blood and midbrain tissue samples
(1) RNA extraction: according to the procedure of the instruction, RNA was extracted from blood and midbrain tissue samples using an RNA extraction kit from TAKARA. Mu.l of the obtained RNA was taken out and quantified.
(2) Reverse transcription: the following was performed using a reverse transcription kit from MedChemExpress, according to the instructions:
reaction system:
2×Super RT Mix 10μL
Total RNA/mRNA 1μg
RNase-Free H2O To 20μL
reaction conditions are as follows:
the first step is as follows: 10 minutes at 25 ℃;
the second step is that: 45 minutes at 42 ℃;
the third step: at 85 ℃ for 2 minutes.
(3) Fluorescent quantitative PCR: according to the instruction steps, the fluorescent quantitative PCR kit of SYBR Green method of Promega company is used for carrying out:
reaction system:
Mice circ-AMOTL1 Forward Primer：CGTCCTGAGGTATCAGCCAC(SEQ ID NO:4)。
Mice circ-AMOTL1 Reverse Primer：AGTTGTTCCTGGATCAGCCG(SEQ ID NO:5)。
reaction conditions are as follows:
the first step is as follows: 2 minutes at 95 ℃;
the second step is that: at 95 ℃ for 15 seconds, at 60 ℃ for 1 minute, for 40 cycles;
the third step: analyzing and determining a target band by a melting curve at 60-95 ℃;
the fourth step: the Δ Δ CT method was used for relative quantification.
4. Whole brain tissue sample staining
(1) Brain tissue treatment: the whole brain tissue obtained in step 2 was fixed in 4% paraformaldehyde sufficiently for 12 hours, and then transferred to a 30% sucrose solution to be dehydrated for 48 hours.
(2) Slicing: sections of the substantia nigra of the midbrain were collected by serial coronal sections of 35 μm thickness of brain tissue in a cryomicrotome.
(3) Immunofluorescence:
1) sections were washed 5 min x 3 times with PBS.
2) Sections were blocked with goat serum for 1 hour.
3) The sections were added with Tyrosine Hydroxylase (TH) -primary antibody at a working titer of 1:1000 and incubated overnight at 4 ℃.
4) The sections were added with goat anti-rabbit fluorescent secondary antibody and incubated for 1 hour at room temperature in the dark.
5) The sections were mounted on glass slides, mounted on neutral resin and stored in the dark.
(4) Counting: the substantia nigra part is observed under a microscope, photographed and counted by the number of the fluorescent cells.
5. Results
(1) As shown in fig. 2 and 3, the expression of circ-AMOTL1 was elevated in both blood and midbrain tissue of mice in the PD 1 day group and PD 7 day group compared to the control group mice, with statistical significance of the difference (p < 0.05).
(2) As shown in fig. 4, the number of TH positive neurons in the black matrix section of the PD 7 day group mice was significantly reduced compared to the control group mice, with statistical significance (p <0.05), but there was no significant change in the number of TH positive neurons in the black matrix section of the PD 1 day group mice, whereas the expression of circ-AMOTL1 in blood and midbrain tissues of the PD 1 day group mice was increased, indicating that the change in circ-AMOTL1 in blood and midbrain tissues was earlier than the loss of neurons.
In conclusion, the invention can detect that the expression of the circular RNA circ-AMOTL1 is increased in the blood of a Parkinson disease patient, the expression of the circular RNA circ-AMOTL1 is also increased in the blood and midbrain tissue of an MPTP-induced Parkinson disease animal model, and the expression change of the circular RNA circ-AMOTL1 is earlier than the neuron loss, so that the circular RNA circ-AMOTL1 can be used for early prediction of the Parkinson disease. Has the advantages of objectivity, sensitivity, simplicity, low cost and the like, and can indicate the risk of the Parkinson's disease at an early stage.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above should not be understood to necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples described in this specification can be combined and combined by those skilled in the art.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Sequence listing
<110> university of mansion
<120> Parkinson disease biomarker and application thereof
<160>5
<170>SIPOSequenceListing 1.0
<210>1
<211>779
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
gaagacccga acccaccccc aaacccgagg accagagggg aaagagaggc cgaggagcgg 60
cagcggaaca gagcagcggc gaccaggaac aacgcggagg caccccaacc gagaacagaa 120
cgcggccaca gcaccaggcc acagggaggc aggaccagcc caccacaaac aaccccacgg 180
aaaacccacc aagaagaccc acaaaggcac cagcagcacg ccaagaaccg cagggcaaga 240
acaccagggg acaaacggga ggagaaacag gccggccacg cagcccagca gaacaacgag 300
gaacgcccac acgaggaggc caaagcacag cgcagccagg gggcagcagc agcagcaaca 360
gcagcagggg gcgggggcca ggacacaggc agggggcacc agcagaagcc cgaacgaggg 420
gaggcccacg gaaccggcca acagggacag gcgcaaagga cgaggcgcga aggaacgaag 480
cagggccacg ccgccgccag cgagagaaca gcagcgcccg gagaggaagg ggccaagcaa 540
cacccccggc cggggaagga aagggccaaa gaggaggggg gcccccccgc ccagccgcag 600
gaaaggcgga ccccggggcc ccaccgagac ccccaagacc aagcaaagag ccccagcagc 660
aagacccagg agcacggaca gggaccagca ccccgggagc ccacgagagg caagcccacc 720
cgccccagcc ggagaacaga gggccgccgc ggaccagcca cccccgagag gggaacgag 779
<210>2
<211>18
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
agaggggaac gaggaaga 18
<210>3
<211>14
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
aggccggaca gccg 14
<210>4
<211>16
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
cgccgaggac agccac 16
<210>5
<211>14
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
aggccggaca gccg 14
Claims (5)
1. The biomarker for the Parkinson's disease is a circular RNA, the circular RNA is circ-AMOTL1, and the circ-AMOTL1 is a nucleotide sequence shown as SEQ ID NO. 1.
2. A method of diagnosing whether a subject has, or predicting the risk of, parkinson's disease or a related disease, for non-disease diagnostic purposes, comprising:
(1) collecting a peripheral blood sample from the subject;
(2) extracting RNA of the peripheral blood sample, performing reverse transcription amplification on the RNA, and then performing fluorescent quantitative PCR (polymerase chain reaction) to detect the expression amount of the circ-AMOTL 1.
3. A kit comprising reagents for detecting the biomarker of claim 1.
4. Use of the biomarker of claim 1 in the manufacture of a kit for diagnosing whether a subject has parkinson's disease or a related disease or predicting the risk of whether a subject has parkinson's disease or a related disease.
5. The use according to claim 4, wherein said diagnosing or prognosing comprises the steps of:
(1) collecting a peripheral blood sample from the subject;
(2) extracting RNA of the peripheral blood sample, performing reverse transcription amplification on the RNA, and then performing fluorescent quantitative PCR (polymerase chain reaction) to detect the expression amount of the circ-AMOTL 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010065567.2A CN111187827A (en) | 2020-01-20 | 2020-01-20 | Parkinson disease biomarker and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010065567.2A CN111187827A (en) | 2020-01-20 | 2020-01-20 | Parkinson disease biomarker and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111187827A true CN111187827A (en) | 2020-05-22 |
Family
ID=70704857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010065567.2A Pending CN111187827A (en) | 2020-01-20 | 2020-01-20 | Parkinson disease biomarker and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111187827A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111893187A (en) * | 2020-08-20 | 2020-11-06 | 广州医科大学附属第二医院 | Use of circ AMOTL1 in prostate cancer bone metastasis |
| CN112813159A (en) * | 2021-03-23 | 2021-05-18 | 广州金域医学检验中心有限公司 | Biomarker of Parkinson's disease and application thereof |
| CN114264756A (en) * | 2022-01-04 | 2022-04-01 | 宝枫生物科技（北京）有限公司 | Biomarker R1 for diagnosing Parkinson's disease and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104903468A (en) * | 2012-11-16 | 2015-09-09 | 西门子公司 | New diagnostic MiRNA markers for parkinson disease |
| CN106434939A (en) * | 2016-10-18 | 2017-02-22 | 乐卫东 | Diagnosis kit for Parkinson's disease, and application of diagnosis kit |
| CN106755563A (en) * | 2017-04-05 | 2017-05-31 | 天津医科大学总医院 | Application of the biomarker in Parkinson is diagnosed |
| CN106913876A (en) * | 2017-02-24 | 2017-07-04 | 南方医科大学 | MiRNA 30a 5p are in Parkinson's detection, treatment, the application of prognosis target spot |
| CN107419008A (en) * | 2017-06-26 | 2017-12-01 | 上海惠皓医疗科技有限公司 | A kind of method and kit of early stage Precise Diagnosis Parkinson's |
| CN108611413A (en) * | 2018-03-30 | 2018-10-02 | 北京泱深生物信息技术有限公司 | A kind of Parkinson's associated biomarkers and its application |
| CN109468373A (en) * | 2018-12-24 | 2019-03-15 | 潘伟 | A kind of biomarker relevant to Parkinson's occurrence and development |
-
2020
- 2020-01-20 CN CN202010065567.2A patent/CN111187827A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104903468A (en) * | 2012-11-16 | 2015-09-09 | 西门子公司 | New diagnostic MiRNA markers for parkinson disease |
| CN106434939A (en) * | 2016-10-18 | 2017-02-22 | 乐卫东 | Diagnosis kit for Parkinson's disease, and application of diagnosis kit |
| CN106913876A (en) * | 2017-02-24 | 2017-07-04 | 南方医科大学 | MiRNA 30a 5p are in Parkinson's detection, treatment, the application of prognosis target spot |
| CN106755563A (en) * | 2017-04-05 | 2017-05-31 | 天津医科大学总医院 | Application of the biomarker in Parkinson is diagnosed |
| CN107419008A (en) * | 2017-06-26 | 2017-12-01 | 上海惠皓医疗科技有限公司 | A kind of method and kit of early stage Precise Diagnosis Parkinson's |
| CN108611413A (en) * | 2018-03-30 | 2018-10-02 | 北京泱深生物信息技术有限公司 | A kind of Parkinson's associated biomarkers and its application |
| CN109468373A (en) * | 2018-12-24 | 2019-03-15 | 潘伟 | A kind of biomarker relevant to Parkinson's occurrence and development |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111893187A (en) * | 2020-08-20 | 2020-11-06 | 广州医科大学附属第二医院 | Use of circ AMOTL1 in prostate cancer bone metastasis |
| CN111893187B (en) * | 2020-08-20 | 2023-09-05 | 广州医科大学附属第二医院 | Application of circ AMOTL1 in prostate cancer bone metastasis |
| CN112813159A (en) * | 2021-03-23 | 2021-05-18 | 广州金域医学检验中心有限公司 | Biomarker of Parkinson's disease and application thereof |
| CN114264756A (en) * | 2022-01-04 | 2022-04-01 | 宝枫生物科技（北京）有限公司 | Biomarker R1 for diagnosing Parkinson's disease and application thereof |
| CN114264756B (en) * | 2022-01-04 | 2024-02-06 | 宝枫生物科技（北京）有限公司 | Biomarker R1 for diagnosing parkinsonism and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111187827A (en) | Parkinson disease biomarker and application thereof | |
| JP6681976B2 (en) | Method for diagnosing early stage Alzheimer's disease or mild cognitive impairment | |
| TWI580788B (en) | Methods and kits for detecting kawasaki disease | |
| CA3050996A1 (en) | Biomarkers of traumatic brain injury | |
| EP3828287B1 (en) | Mci diagnosis marker due to ad and application thereof | |
| WO2000040749A9 (en) | Method for the detection of gene transcripts in blood and uses thereof | |
| CN104480106B (en) | Detection Patients with Mild Cognitive Impairment serum/plasma Microrna mark and its application | |
| US20180251837A1 (en) | Use of mirco-rnas circulating in the blood serum or blood plasma for identifying patients requiring a biopsy and as a marker for the differential diagnosis of individual non-ischemic cardiomyopathies or storage diseases | |
| CN109136358B (en) | Reagent for identifying and diagnosing residual sperms in testis of NOA patient and application of miRNA in reagent | |
| EP1548129A1 (en) | Method of diagnosing integration dysfunction syndrome using blood | |
| CN114015767B (en) | Serum circRNA marker for identifying craniosynostosis and application thereof | |
| CN113025705B (en) | Application of miRNA-214 as biomarker of Parkinson disease precursor stage | |
| CN115976189A (en) | Biomarker for cerebral infarction diagnosis and detection and related application thereof | |
| US11685950B2 (en) | Method of diagnosing and treating acute rejection in kidney transplant patients | |
| CN113151450A (en) | Biomarker for early diagnosis of sporadic amyotrophic lateral sclerosis and Parkinson's disease and application of biomarker | |
| CN114150050B (en) | System, method and method establishment for IgA nephropathy detection | |
| TWI626314B (en) | Method for accessing the risk of having colorectal cancer | |
| US11655507B2 (en) | Method for diagnosing Parkinson's disease using nasal mucus, composition therefore, and kit comprising the same | |
| CN106544435A (en) | Needed for detection miR 206, reverse transcriptase primer is to the application in prediction test kit is prepared | |
| TWI703218B (en) | Use of biomarker for diagnosing bipolar ii disorder | |
| KR20210088053A (en) | Method and kit for diagnosis of diabetic neuropathy using micro-rna | |
| KR20180078783A (en) | A novel miRNA for diagnosing Alzheimer’s disease | |
| EP2687607B1 (en) | MicroRNA profiles in the diagnosis of multiple sclerosis | |
| CN108277268B (en) | Peripheral blood marker-plasma free DNA for diagnosing schizophrenia | |
| CN115851916A (en) | Application of mitochondrial complex I key gene MT-ND6 in systemic lupus erythematosus diagnostic kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200522 |
|
| RJ01 | Rejection of invention patent application after publication |